Virginia Patent of the Month – December 2023

Purnovate, Inc. is working to unlock the power of adenosine, developing novel drugs that target these adenosine receptors. Adenosine receptors are known to be involved in numerous chronic diseases including asthma and COPD. Purnovate’s approach uses antagonists of these adenosine receptors to treat patients more effectively.

The company has recently patented their cyclic amide-containing pyridyl xanthines – a special formulation that acts specifically as A2B antagonists. 

Adenosine is a naturally occurring compound often found in tissues under stress. By binding to the four adenosine receptors (A1R, A2AR, A2BR, A3R), it modulates important functions such as cardiac rhythm, sleep, immune system response, metabolism, angiogenesis, and other cell functions. By targeting only the A2B antagonist, the treatment can avoid unwanted side effects. This achieves greater selectivity than previously attempted treatments.

Purnovate’s adenosine platform is a cornerstone of their company. They intend to continue down this development path, broadening their future drug pipeline efficiently and econmically.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts